iData Insights

Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation Now Available at iData Insights

Press Release   •   Jan 02, 2016 15:02 IST

Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation Summary Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the management of recurrent and later-stage disease is largely reliant on cytotoxic chemotherapy regimens. A highly active ovarian cancer pipeline contains an array of diverse molecule types and molecular targets, in contrast to the market. With the diversity in the pipeline, there is hope that innovative products can make it to market to provide patients with greater therapeutic options, while meeting unmet needs within ovarian cancer. There are 179 ovarian cancer pipeline products associated with a first-in-class molecular target representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. Such a diverse and innovative pipeline implies that approaches to ovarian cancer treatment are changing and first-in-class development is playing a significant role in this. Scope Chemotherapy based regimens continue to dominate the market, which has seen few new entrants over the past decade. Lynparza (olaparib) is a key new entrant; however it is only effective in a small patient subset. - What survival benefits do current therapies provide? - What are the current unmet needs that the pipeline needs to address? The pipeline places increased focus on targeted therapies, including a large number of therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt. - What potential do mAbs have in ovarian cancer treatment? - Will pipeline diversity translate to clinically and commercially successful therapies? - How are common target families, such as intracellular signal transduction associated with pathophysiology? 52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages. - Do first-in-class products show strong progression into the later stages? - Why is the greatest number of first-in-class products seen in signal transduction? First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways - How well are first-in-class targets, such as Notch, aligned to known disease causing pathways? - Which targets are specifically found in early-stage development? - What is the industry-wide interest in these targets? Co-development deals for first-in-class products are typically higher value than non-first-in-class counterparts. - To what extent does first-in-class status influence deal value and phase? - Can biologics command a greater deal value than other molecule types? Reasons to buy This report will allow you to - - Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis. - Visualize the composition of the ovarian cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market. - Analyze the ovarian cancer pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches the treating ovarian cancer. - Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail. - Identify commercial opportunities in the ovarian cancer deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of ovarian cancer therapies that are not yet involved in deals and may be potential investment opportunities.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 4

2.1 Significant Unmet Needs in the Ovarian Cancer Market 4

2.2 High Proportion of First-in-Class Innovation offers Promise in Ovarian Cancer 4

2.3 Deal Activity Varies with First-in-Class Status 4

3 The Case for Innovation 5

3.1 Growing Opportunities for Biologic Products 6

3.2 Diversification of Molecular Targets 6

3.3 Innovative First-in-Class Product Developments Remain Attractive 6

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7

3.5 Sustained Innovation 7

3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 9

4.1 Disease Overview 9

4.2 Disease Symptoms 9

4.3 Epidemiology and Etiology 9

4.4 Pathophysiology 10

4.4.1 High-Grade Serous Subtype 10

4.4.2 Low-Grade Serous Subtype 11

4.4.3 Mucinous Carcinoma Subtype 11

4.4.4 Endometrioid Carcinoma Subtype 11

4.4.5 Clear Cell Carcinoma Subtype 11

4.5 Diagnosis 12

4.6 Prognosis 12

4.7 Treatment Algorithm 12

4.7.1 Surgery 12

4.7.2 First-Line Therapy 12

4.7.3 Maintenance Therapy 14

4.7.4 Recurrent Disease and Second-Line Therapy 15

4.8 Overview of Marketed Products in Ovarian Cancer 18

4.8.1 Molecule Type and Target Analysis 18

4.8.2 Innovative Products in Ovarian Cancer Market 19

4.8.3 Unmet Needs 20

5 Assessment of Pipeline Product Innovation 21

5.1 Ovarian Cancer Pipeline by Molecule Type, Phase and Therapeutic Target 21

5.2 Comparative Distribution of Programs between Ovarian Cancer Market and Pipeline by Therapeutic Target Family 25

5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 26

6 Signaling Network, Disease Causation and Innovation Alignment 32

6.1 Complexity of Signaling Networks in Oncology 32

6.2 Signaling Pathways and First-in-Class Molecular Target Integration 33

6.3 First-in-Class Matrix Assessment 33

7 First-in-Class Target Evaluation 37

7.1 Pipeline Programs Targeting Mucin 16 and Mucin 1 37

7.2 Pipeline Programs Targeting Notch 38

7.3 Pipeline Programs Targeting 3-Phosphoinositide-Dependent Protein Kinase 1 39

7.4 Pipeline Programs Targeting G2/Mitotic-Specific Cyclin B1 40

7.5 Pipeline Programs Targeting Cell Division Cycle 7-Related Protein Kinase 40

7.6 Pipeline Programs Targeting X-Linked Inhibitor of Apoptosis Protein 41

7.7 Pipeline Programs Targeting Cyclin-Dependent Kinase 2 42

7.8 Pipeline Programs Targeting PIK3CA 43

7.9 Pipeline Products Targeting HDAC 10, 4, 5 and 7 44

7.10 Conclusion 45

8 Deals and Strategic Consolidations 46

8.1 Industry-Wide First-in-Class Deals 46

8.2 Licensing Deals 47

8.2.1 Licensing Deals by Molecule Type 51

8.2.2 Licensing Deals by Molecular Target 52

8.2.3 Conclusion 52

8.3 Co-development Deals 53

8.3.1 Co-development Deals by Molecule Type 55

8.3.2 Co-development Deals by Molecular Target 56

8.3.3 Conclusion 56

8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 56

9 Appendix 60

9.1 References 60

9.2 Abbreviations 62

9.3 Research Methodology 63

9.4 Secondary Research 64

9.4.1 Marketed Product Heatmaps and Treatment Algorithm 64

9.4.2 Pipeline Analysis 64

9.4.3 First-in-Class Matrix Assessment 64

9.4.4 First-in-Class Target Profiles 65

9.4.5 Licensing and Co-Development Deals 65

9.5 Contact Us 65

9.6 Disclaimer 65

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects